Literature DB >> 14707226

Leprosy: a primer for Canadian physicians.

Andrea K Boggild1, Jay S Keystone, Kevin C Kain.   

Abstract

Leprosy is a rare but serious infectious disease caused by Mycobacterium leprae. While global prevalence of the disease is decreasing, increasing rates of immigration from countries where leprosy is endemic have led to the recognition of this illness in North America. Classically, leprosy presents as hypopigmented cutaneous macules along with sensory and motor peripheral neuropathies, although the clinical manifestations vary along a disease spectrum. In addition to primary infection, patients may undergo a "reaction," an acute inflammatory response to the mycobacterium, which leads to pain and erythema of skin lesions and dangerous neuritis. Reactions can occur at any time during the course of leprosy, but they tend to be precipitated by treatment. They are a significant cause of impaired quality of life due to marked nerve damage and thus warrant prompt intervention. Although leprosy may have a protracted onset and be difficult to recognize, cure is achievable with appropriate multidrug therapy. Because untreated leprosy can result in permanent, irreversible nerve damage and secondary transmission, early diagnosis and treatment are essential to minimize morbidity.

Entities:  

Mesh:

Year:  2004        PMID: 14707226      PMCID: PMC305320     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  35 in total

1.  Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group.

Authors: 
Journal:  Indian J Lepr       Date:  1997 Apr-Jun

2.  A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar.

Authors:  J Bertolli; C Pangi; R Frerichs; M E Halloran
Journal:  Int J Epidemiol       Date:  1997-08       Impact factor: 7.196

3.  Armadillo exposure among Mexican-born patients with lepromatous leprosy.

Authors:  D A Thomas; J S Mines; D C Thomas; T M Mack; T H Rea
Journal:  J Infect Dis       Date:  1987-12       Impact factor: 5.226

Review 4.  Indeterminate leprosy. A passing phase in the evolution of leprosy.

Authors:  V N Sehgal; G Srivastava
Journal:  Lepr Rev       Date:  1987-09       Impact factor: 0.537

5.  Susceptibility to leprosy is linked to the human NRAMP1 gene.

Authors:  L Abel; F O Sánchez; J Oberti; N V Thuc; L V Hoa; V D Lap; E Skamene; P H Lagrange; E Schurr
Journal:  J Infect Dis       Date:  1998-01       Impact factor: 5.226

6.  Field treatment of acute nerve function impairment in leprosy using a standardized corticosteroid regimen--first year's experience with 100 patients.

Authors:  R P Croft; J H Richardus; W C Smith
Journal:  Lepr Rev       Date:  1997-12       Impact factor: 0.537

7.  BC's "Island of death" marked a sad chapter in Canada's medical history.

Authors:  P Johnston
Journal:  CMAJ       Date:  1995-03-15       Impact factor: 8.262

Review 8.  Environmental nonhuman sources of leprosy.

Authors:  L A Blake; B C West; C H Lary; J R Todd
Journal:  Rev Infect Dis       Date:  1987 May-Jun

9.  Leprosy in children: a prospective study.

Authors:  V N Sehgal; A K Chaudhry
Journal:  Int J Dermatol       Date:  1993-03       Impact factor: 2.736

10.  Leprosy reversal reaction in HIV-positive patients.

Authors:  L Blum; B Flageul; S Sow; P Launois; M D Vignon-Pennamen; A Coll; J Millan
Journal:  Int J Lepr Other Mycobact Dis       Date:  1993-06
View more
  10 in total

1.  [Tuberculoid leprosy ("Single skin lesion")].

Authors:  J Rieker; S Ritzmann; C Talhari; B Homey; T Ruzicka; D Bruch-Gerharz
Journal:  Hautarzt       Date:  2005-10       Impact factor: 0.751

2.  [Not Available].

Authors:  Jean Milot
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-03       Impact factor: 2.471

3.  Arthritis, progressive maculopapular rash and severe peripheral neuropathy in a 60-year-old man. Diagnosis: Leprosy.

Authors:  François Tremblay; Martin Albert
Journal:  CMAJ       Date:  2013-12-23       Impact factor: 8.262

Review 4.  Leprosy in the 21st century.

Authors:  Cassandra White; Carlos Franco-Paredes
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

5.  Association of cytokine gene polymorphism with susceptibility and clinical types of leprosy.

Authors:  A Settin; S Nassar; A Abdel-Latif; R Elbaz; S El-Mongy; Aa Hassan; Am Hassan
Journal:  Int J Health Sci (Qassim)       Date:  2007-01

6.  Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy.

Authors:  Jeffrey Craig; Cara MacRae; Rochelle G Melvin; Andrea K Boggild
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

Review 7.  A review of nutrition in neuropathic pain of leprosy.

Authors:  Michael Klowak; Andrea K Boggild
Journal:  Ther Adv Infect Dis       Date:  2022-06-01

8.  Leprosy in Toronto: an analysis of 184 imported cases.

Authors:  Andrea K Boggild; Jason D Correia; Jay S Keystone; Kevin C Kain
Journal:  CMAJ       Date:  2004-01-06       Impact factor: 8.262

9.  Epidemiology of Leprosy in Iran from 2005 to 2015.

Authors:  Kamyar Mansori; Erfan Ayubi; Mahshid Nasehi; Shiva Mansouri Hanis; Behzad Amiri; Salman Khazaei
Journal:  Tanaffos       Date:  2017

10.  Evaluation of safety tool for ambulatory leprosy patients at risk of adverse outcome.

Authors:  Cara MacRae; Swana Kopalakrishnan; Lena Faust; Michael Klowak; Adrienne Showler; Stefanie A Klowak; Andrea K Boggild
Journal:  Trop Dis Travel Med Vaccines       Date:  2018-03-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.